Advanced in Choledocholithiasis

Jayanta Samanta

Chandigarh, CH, IN 
Advanced in Choledocholithiasis
Chandigarh, CH, IN 
OverviewLocationsClinical Research

Overview

Jayanta Samanta practices in Chandigarh, India. Samanta is rated as an Advanced expert by MediFind in the treatment of Choledocholithiasis. Their top areas of expertise are Acute Pancreatitis, Hereditary Pancreatitis, Necrosis, Endoscopy, and Gallbladder Removal.

Their clinical research consists of co-authoring 210 peer reviewed articles and participating in 3 clinical trials. MediFind looks at clinical research from the past 15 years. In particular, they have co-authored 5 articles in the study of Choledocholithiasis.

Locations

Chandigarh, CH, India
Other Locations
Kattankulathur, TN 603203, India
Ghaziabad, UP 201002, India
Chandigarh, PB, India
4 Raja S. C. Mullick Road, Jadavpur, 700 032, Kolkata, WB, India

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Experts who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

3 Clinical Trials

A Phase 3, Multicenter, Open-Label, Long-Term Extension Study to Evaluate the Long-Term Efficacy and Safety of Mirikizumab in Patients With Crohn's Disease
A Phase 3, Multicenter, Open-Label, Long-Term Extension Study to Evaluate the Long-Term Efficacy and Safety of Mirikizumab in Patients With Crohn's Disease
Enrollment Status: Active_not_recruiting
Publish Date: April 18, 2025
Intervention Type: Drug
Study Drug: Mirikizumab
Study Phase: Phase 3
A Phase 3, Multicenter, Randomized, Double-Blind, Placebo- and Active- Controlled, Treat-Through Study to Evaluate the Efficacy and Safety of Mirikizumab in Patients With Moderately to Severely Active Crohn's Disease
A Phase 3, Multicenter, Randomized, Double-Blind, Placebo- and Active- Controlled, Treat-Through Study to Evaluate the Efficacy and Safety of Mirikizumab in Patients With Moderately to Severely Active Crohn's Disease
Enrollment Status: Completed
Publish Date: December 27, 2024
Intervention Type: Drug
Study Drugs: Mirikizumab, Ustekinumab
Study Phase: Phase 3
An Adaptive Phase 2, Randomized, Double Blind, Placebo Controlled Study of LY3471851 (NKTR 358) in Patients With Moderately to Severely Active Ulcerative Colitis
An Adaptive Phase 2, Randomized, Double Blind, Placebo Controlled Study of LY3471851 (NKTR 358) in Patients With Moderately to Severely Active Ulcerative Colitis
Enrollment Status: Terminated
Publish Date: September 05, 2023
Intervention Type: Drug
Study Drug: LY3471851
Study Phase: Phase 2
View 2 Less Clinical Trials

210 Total Publications

Mucosal islands in ulcerative colitis: A simple clue of severity on an abdominal radiograph.
Mucosal islands in ulcerative colitis: A simple clue of severity on an abdominal radiograph.
Journal: Tropical doctor
Published: October 08, 2025

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Samanta's expertise for a condition
ConditionClose
View All 12 Advanced Conditions
View All 57 Experienced Conditions
Want to save this expert for later?
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
 
 
 
 
Learn about our expert tiers
Learn More
Are you the provider on this profile?
Claim Profile